Literature DB >> 22302900

Phospho-specific flow: fixating on the target.

Mark Levis1.   

Abstract

Targeted therapies are all the rage in oncology research these days. The problem remains as to how to confirm that the target is actually being hit in vivo. This report describes the application of phospho-specific flow cytometry to establish in vivo target inhibition in real time.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22302900      PMCID： PMC3306466          DOI： 10.1158/1078-0432.CCR-11-3266

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry.

Authors:  Omar D Perez; Garry P Nolan
Journal:  Nat Biotechnol       Date:  2002-02       Impact factor: 54.908

2.  mTOR regulates cell survival after etoposide treatment in primary AML cells.

Authors:  Qing Xu; James E Thompson; Martin Carroll
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

Authors:  J Baselga; D Rischin; M Ranson; H Calvert; E Raymond; D G Kieback; S B Kaye; L Gianni; A Harris; T Bjork; S D Averbuch; A Feyereislova; H Swaisland; F Rojo; J Albanell
Journal:  J Clin Oncol       Date:  2002-11-01       Impact factor: 44.544

4.  Protein Interactions Captured by Chemical Cross-linking: One-Step Cross-linking with Formaldehyde.

Authors:  Owen W Nadeau; Gerald M Carlson
Journal:  CSH Protoc       Date:  2007-04-01

5.  Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum.

Authors:  Sean C Bendall; Erin F Simonds; Peng Qiu; El-ad D Amir; Peter O Krutzik; Rachel Finck; Robert V Bruggner; Rachel Melamed; Angelica Trejo; Olga I Ornatsky; Robert S Balderas; Sylvia K Plevritis; Karen Sachs; Dana Pe'er; Scott D Tanner; Garry P Nolan
Journal:  Science       Date:  2011-05-06       Impact factor: 47.728

6.  Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.

Authors:  Mark Levis; Patrick Brown; B Douglas Smith; Adam Stine; Rosalyn Pham; Richard Stone; Daniel Deangelo; Ilene Galinsky; Frank Giles; Elihu Estey; Hagop Kantarjian; Pamela Cohen; Yanfeng Wang; Johannes Roesel; Judith E Karp; Donald Small
Journal:  Blood       Date:  2006-07-20       Impact factor: 22.113

Review 7.  mTOR: from growth signal integration to cancer, diabetes and ageing.

Authors:  Roberto Zoncu; Alejo Efeyan; David M Sabatini
Journal:  Nat Rev Mol Cell Biol       Date:  2010-12-15       Impact factor: 94.444

8.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

9.  Single cell profiling of potentiated phospho-protein networks in cancer cells.

Authors:  Jonathan M Irish; Randi Hovland; Peter O Krutzik; Omar D Perez; Øystein Bruserud; Bjørn T Gjertsen; Garry P Nolan
Journal:  Cell       Date:  2004-07-23       Impact factor: 41.582

10.  Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.

Authors:  Nikesh Kotecha; Nikki J Flores; Jonathan M Irish; Erin F Simonds; Debbie S Sakai; Sophie Archambeault; Ernesto Diaz-Flores; Marc Coram; Kevin M Shannon; Garry P Nolan; Mignon L Loh
Journal:  Cancer Cell       Date:  2008-10-07       Impact factor: 31.743
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.